Susan Mennenga
Clinical Researcher
Data updated
Papers
Trials
Research Footprint
Susan Mennenga appears in 9 tracked papers (2016–2026), most studied alongside Psilocybin, MDMA and Ketamine, across Depressive Disorders, Anxiety Disorders and Palliative & End-of-Life Distress.
Most-cited paper: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial (1678 citations).
Frequent co-authors: Stephen Ross, Michael Bogenschutz and Gabrielle Agin-Liebes.
Background & Research
Susan E. Mennenga is a clinical researcher involved in multiple clinical investigations of psilocybin-assisted psychotherapy, with a focus on psychiatric and existential distress in patients with life‑threatening cancer and on therapeutic processes in alcohol use disorder. Her work, as represented in several clinical papers, emphasises both quantitative clinical outcomes (including reductions in loss of meaning, suicidality, anxiety and depressive symptoms) and detailed qualitative clinical interpretations of patient experience.
Mennenga has contributed to studies reporting acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy in oncology populations, detailed individual case narratives from cancer patients, long-term follow-up outcomes, and analyses of personality change and clinical interpretation in a double-blind, placebo-controlled trial for alcohol use disorder. Her contributions are characterised by integration of clinical assessment, psychotherapy process evaluation, and patient-centred outcome measurement, advancing understanding of both therapeutic effects and subjective experience in contemporary psychedelic-assisted therapy trials.
Key Impact
Contributor to clinical investigations of psilocybin-assisted psychotherapy, particularly for cancer-related existential distress and for alcohol use disorder, with work spanning acute, long-term and qualitative patient-outcome analyses.
Collaboration Network
11 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Susan Mennenga's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Susan Mennenga is associated with.
NYU Center for Psychedelic Medicine
The NYU Langone Center for Psychedelic Medicine sits within the Department of Psychiatry at NYU Grossman School of Medicine in New York, and builds on a research group that has studied psychedelics since the early 2010s. Established in 2021 with philanthropic support, it is directed by Michael Bogenschutz, whose randomised trial of psilocybin-assisted therapy for alcohol use disorder, published in 2022, is among the most cited in the field. The centre runs translational and clinical research across psychiatry and addiction medicine, and places particular weight on training the next generation of investigators and therapists through a dedicated research fellowship. Its work spans alcohol and other substance use disorders, PTSD and related conditions.
View stakeholder →NYU Grossman School of Medicine
NYU Grossman School of Medicine is New York University's medical school and a core academic unit of NYU Langone Health. It provides MD and other medical education, conducts biomedical research, and delivers clinical care in the United States.
View stakeholder →NYU Langone Health
Home to the NYU Langone Center for Psychedelic Medicine, one of the world's leading academic institutions in psychedelic research. Has conducted landmark psilocybin trials for smoking cessation, alcohol use disorder, and depression in cancer patients, spearheaded by Dr. Michael Bogenschutz and colleagues.
View stakeholder →